IPO Listed
Apnimed IPO
US$192m raised
Lodged 30 Jul 2026 · NASDAQ: APMD · US$16.00 cash per share
Advisers
Lead managers
- Bookrunner
- Legal adviser
- Issuer
- Apnimed
- Issuer based in
- United States
- Listed
- 31 Jul 2026
- Sector
- Biotech
- Tags
- Biotech, Drug Development
In the league tables
Similar deals
- AbCellera Biologics equity raising Aug 2026 · US$200m · Biotech
- Sensei Biotherapeutics placement Feb 2026 · US$200m · Biotech
- Silence Therapeutics placement Aug 2026 · US$201m · Biotech
- Agomab Therapeutics NV IPO Feb 2026 · US$200m · Biotech
- Processa Pharmaceuticals placement Jul 2026 · US$200m · Biotech
Sources
- 30 Jul 2026 Evercore: Active bookrunner on Apnimed’s initial public offering evercore.com
- 31 Jul 2026 Final IPO prospectus (424B4), Apnimed, Inc. sec.gov
- 4 Aug 2026 Goodwin Advises Apnimed, Inc., on $220.8 Million IPO Including Full Exercise of the Underwriters’ Over-Allotment Option goodwinlaw.com




